{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:47:24Z","timestamp":1792298844124,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.rmed.2016.11.011","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T22:03:53Z","timestamp":1479161033000},"page":"58-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Long-term general and cardiovascular safety of tiotropium\/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"122","author":[{"given":"Roland","family":"Buhl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon","family":"Magder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Bothner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Vo\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaro","family":"Loaiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus F.","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorcan","family":"McGarvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.rmed.2016.11.011_bib1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.300.12.1439","article-title":"Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"300","author":"Singh","year":"2008","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.rmed.2016.11.011_bib2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1164\/rccm.201209-1739PP","article-title":"\u03b22-agonist therapy in lung disease","volume":"187","author":"Cazzola","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2016.11.011_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-2600(15)00518-4","article-title":"Cardiac effects of current treatments of chronic obstructive pulmonary disease","volume":"4","author":"Lahousse","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2016.11.011_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/15412550600977544","article-title":"Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events?","volume":"3","author":"Calverley","year":"2006","journal-title":"COPD"},{"issue":"6","key":"10.1016\/j.rmed.2016.11.011_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.rce.2012.02.014","article-title":"Comorbidities in patients hospitalized due to chronic obstructive pulmonary disease. A comparative analysis of the ECCO and ESMI studies","volume":"212","author":"Almagro","year":"2012","journal-title":"Rev. Clin. Esp."},{"issue":"5","key":"10.1016\/j.rmed.2016.11.011_bib6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1183\/09031936.00128008","article-title":"Systemic manifestations and comorbidities of COPD","volume":"33","author":"Barnes","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2016.11.011_bib7","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1378\/chest.128.4.2005","article-title":"Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001","volume":"128","author":"Holguin","year":"2005","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.rmed.2016.11.011_bib8","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/thx.2009.128082","article-title":"Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care","volume":"65","author":"Feary","year":"2010","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.rmed.2016.11.011_bib9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Gold executive summary","volume":"176","author":"Rabe","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2016.11.011_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/COPD.S39018","article-title":"The safety of long-acting \u03b22-agonists in the treatment of stable chronic obstructive pulmonary disease","volume":"8","author":"Decramer","year":"2013","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"Suppl 59","key":"10.1016\/j.rmed.2016.11.011_bib11","article-title":"Study to understand mortality and morbidity in COPD (SUMMIT)","volume":"46","author":"Vestbo","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2016.11.011_bib12","author":"Boehringer Ingelheim Pharmaceuticals"},{"issue":"15","key":"10.1016\/j.rmed.2016.11.011_bib13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A\u00a04-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"10","key":"10.1016\/j.rmed.2016.11.011_bib14","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.rmed.2010.06.004","article-title":"A\u00a0one-year trial of tiotropium Respimat\u00ae plus usual therapy in COPD patients","volume":"104","author":"Bateman","year":"2010","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2016.11.011_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1378\/chest.12-2613","article-title":"Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial","volume":"144","author":"Cooper","year":"2013","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2016.11.011_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4187\/respcare.00852","article-title":"Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes","volume":"56","author":"Yohannes","year":"2011","journal-title":"Respir. Care"},{"issue":"12","key":"10.1016\/j.rmed.2016.11.011_bib17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"16","key":"10.1016\/j.rmed.2016.11.011_bib18","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","article-title":"Tiotropium Respimat inhaler and the risk of death in COPD","volume":"369","author":"Wise","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"10","key":"10.1016\/j.rmed.2016.11.011_bib19","article-title":"Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease","author":"Farne","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2016.11.011_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.110.167007","article-title":"Pharmacological characterization of olodaterol, a novel inhaled \u03b22-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models","volume":"334","author":"Bouyssou","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.rmed.2016.11.011_bib21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/jpet.111.179259","article-title":"Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol","volume":"337","author":"Casarosa","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"Suppl 57","key":"10.1016\/j.rmed.2016.11.011_bib22","article-title":"The 24-h FEV1 time profile of olodaterol QD delivered via Respimat\u00ae in COPD: results from two 6-week studies","volume":"42","author":"Lange","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"No.4 Meeting Abstracts","key":"10.1016\/j.rmed.2016.11.011_bib23","article-title":"The 24-hour FEV1 time profile of olodaterol once daily (QD) via Respimat\u00ae and formoterol twice daily (BID) via Aerolizer\u00ae in patients with COPD: results from two 6-week studies","volume":"144","author":"Feldman","year":"2013","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2016.11.011_bib24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"Meeting Abstracts","key":"10.1016\/j.rmed.2016.11.011_bib25","article-title":"Effect of tiotropium\u00a0+\u00a0olodaterol therapy on COPD exacerbations in the TONADO\u00ae studies","volume":"193","author":"Derom","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2016.11.011_bib26","first-page":"239","article-title":"Tiotropium HandiHaler\u00ae and Respimat\u00ae in COPD: a pooled safety analysis","volume":"10","author":"Halpin","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"5","key":"10.1016\/j.rmed.2016.11.011_bib27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3109\/15412555.2014.991864","article-title":"One-year safety of olodaterol once daily via Respimat\u00ae in patients with GOLD 2\u20134 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis","volume":"12","author":"McGarvey","year":"2015","journal-title":"COPD"},{"issue":"10","key":"10.1016\/j.rmed.2016.11.011_bib28","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.rmed.2014.07.011","article-title":"Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients","volume":"108","author":"Wedzicha","year":"2014","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2016.11.011_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1465-9921-15-78","article-title":"Safety and tolerability of once-daily umeclidinium\/vilanterol 125\/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study","volume":"15","author":"Donohue","year":"2014","journal-title":"Respir. Res."},{"issue":"10","key":"10.1016\/j.rmed.2016.11.011_bib30","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","article-title":"Tiotropium\u00a0+\u00a0olodaterol shows clinically meaningful improvements in quality of life","volume":"109","author":"Singh","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2016.11.011_bib31","author":"Food and Drug Administration"},{"issue":"8","key":"10.1016\/j.rmed.2016.11.011_bib32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611116302992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611116302992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:35:27Z","timestamp":1760614527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611116302992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":32,"alternative-id":["S0954611116302992"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2016.11.011","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term general and cardiovascular safety of tiotropium\/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2016.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}